| 1.01 0 (0%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.69 | 1-year : | 1.97 |
| Resists | First : | 1.45 | Second : | 1.69 |
| Pivot price | 1.41  |
|||
| Supports | First : | 0.56 | Second : | 0.01 |
| MAs | MA(5) : | 1.39 | MA(20) : | 1.33 |
| MA(100) : | 1.3 |
MA(250) : | 1.66 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.9 |
D(3) : | 78.1 |
| RSI | RSI(14): 55.5 | |||
| 52-week | High : | 3.77 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PROC ] has closed above bottom band by 34.9%. Bollinger Bands are 85.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.4 - 1.41 | 1.41 - 1.42 |
| Low: | 1.38 - 1.39 | 1.39 - 1.4 |
| Close: | 1.39 - 1.4 | 1.4 - 1.41 |
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Mon, 03 Feb 2025
Procaps Group Receives Delisting Notice From Nasdaq - GlobeNewswire
Fri, 03 Jan 2025
Procaps Group Faces New Nasdaq Delinquency Notice Over Missing Financial Statements - Stock Titan
Fri, 20 Dec 2024
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates - GlobeNewswire
Tue, 03 Dec 2024
Procaps Group Announces Financing, Shareholders Agreement and Board Updates - GlobeNewswire
Thu, 10 Oct 2024
Procaps Issues Shareholder Letter Update - Yahoo Finance
Fri, 28 Jun 2024
Procaps Group Announces New Chairman - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 113 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 83 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 114 (K) |
| Shares Short P.Month | 163 (K) |
| EPS | 0.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | 12.6 % |
| Operating Margin | 11.1 % |
| Return on Assets (ttm) | 6.2 % |
| Return on Equity (ttm) | 373.7 % |
| Qtrly Rev. Growth | 7.3 % |
| Gross Profit (p.s.) | 2.02 |
| Sales Per Share | 3.67 |
| EBITDA (p.s.) | 0.5 |
| Qtrly Earnings Growth | -63.8 % |
| Operating Cash Flow | 63 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | 2.12 |
| PEG Ratio | 0 |
| Price to Book value | 3.58 |
| Price to Sales | 0.38 |
| Price to Cash Flow | 2.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|